C
22.91
0.63 (2.83%)
| Previous Close | 22.28 |
| Open | 22.91 |
| Volume | 1,160,896 |
| Avg. Volume (3M) | 1,331,418 |
| Market Cap | 4,922,053,120 |
| Price / Sales | 11.81 |
| Price / Book | 16.41 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 |
| Profit Margin | -82.28% |
| Operating Margin (TTM) | 18.20% |
| Diluted EPS (TTM) | -1.58 |
| Quarterly Revenue Growth (YOY) | 26.90% |
| Total Debt/Equity (MRQ) | 4.11% |
| Current Ratio (MRQ) | 1.84 |
| Operating Cash Flow (TTM) | 110.03 M |
| Levered Free Cash Flow (TTM) | -72.34 M |
| Return on Assets (TTM) | 6.35% |
| Return on Equity (TTM) | -188.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Software - Infrastructure (US) | Mixed | Bullish |
| Software - Infrastructure (Global) | Mixed | Bullish | |
| Stock | Cellebrite DI Ltd. | Bullish | Bullish |
AIStockmoo Score
2.5
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.50 |
|
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker. |
|
| Sector | Technology |
| Industry | Software - Infrastructure |
| Investment Style | Mid Growth |
| % Held by Insiders | 46.79% |
| % Held by Institutions | 53.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Crosslink Capital Inc | 30 Sep 2024 | 3,486,945 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Needham, 22.22%) | Buy |
| Median | 24.00 (4.76%) | |
| Low | 24.00 (Craig-Hallum, 4.76%) | Buy |
| 24.00 (JP Morgan, 4.76%) | Buy | |
| Average | 25.33 (10.56%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 20.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 22 Jan 2025 | 28.00 (22.22%) | Buy | 23.87 |
| 07 Nov 2024 | 21.00 (-8.34%) | Buy | 18.79 | |
| JP Morgan | 16 Dec 2024 | 24.00 (4.76%) | Buy | 20.29 |
| 07 Nov 2024 | 22.00 (-3.97%) | Buy | 18.79 | |
| Craig-Hallum | 07 Nov 2024 | 24.00 (4.76%) | Buy | 18.79 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Jan 2025 | Announcement | Cellebrite to Report Fourth-Quarter and Fiscal Year 2024 Financial Results on February 13, 2025 |
| 08 Jan 2025 | Announcement | Cellebrite Announces Participation in the 27th Annual Needham & Company Growth Conference |
| 06 Jan 2025 | Announcement | Cellebrite Appoints Michael D. Capellas to Board of Directors as Lead Independent Director |
| 25 Nov 2024 | Announcement | Cellebrite Announces Participation in the UBS Global Technology and AI Conference |
| 20 Nov 2024 | Announcement | Cellebrite and Relativity Deliver Solutions to Transform the Mobile Data Collection Landscape |
| 06 Nov 2024 | Announcement | CORRECTION: Cellebrite Announces Third-Quarter 2024 Results |
| 06 Nov 2024 | Announcement | Yossi Carmil to Step Down as CEO After Nearly 20 Years |
| 06 Nov 2024 | Announcement | Cellebrite Announces Third-Quarter 2024 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |